

mTOR Inhibitors Market Forecasted to Achieve US \$9.71 Billion by 2029

The Business Research Company's mTOR Inhibitors Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, November 25, 2025

[/Einpresswire.com/](https://www.einpresswire.com/) -- "Get 20% Off All Global Market Reports With Code

ONLINE20 - Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors



How Big Is The [mTOR Inhibitors Market](#) In 2025?

The size of the mTOR inhibitors market has experienced consistent growth in the past few years.



Get 20% Off All Global Market Reports With Code ONLINE20 - Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors"

The Business Research Company

It is projected to increase from \$7.43 billion in 2024 to \$7.74 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.2%. The noticeable expansion during the historic period can be associated with factors such as advancements in oncology treatment, the treatment of renal cell carcinoma, transplantation medicine, the progress made in clinical research and drug development, as well as applications in immunosuppression.

In the upcoming years, the market size for mTOR inhibitors is anticipated to experience significant growth, reaching

""\$9.71 billion in 2029"" with a compound annual growth rate (CAGR) of 5.9%. Factors contributing to this anticipated growth during the forecast period include the increase in oncology indications, precision medicine advancements, rise in transplantation instances, management of chronic diseases, and a rising aged population. The forecast period is also expected to witness certain significant trends such as the exploration of neuroprotective effects, increased use in transplant medicine, growing interest in metabolic disorders, collaboration in drug development, and global health initiatives for rare diseases.

Download a free sample of the mtor inhibitors market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=10860&type=smp>

What Are The Key Driving Factors For The Growth Of The mTOR Inhibitors Market?

The increasing occurrence of kidney diseases globally is projected to fuel the expansion of the mTOR inhibitors market. Kidney diseases, characterized by the progressive impairment and loss of organ function, can be treated using mTOR inhibitors. They form part of immunosuppressive therapies, including mTOR inhibitors like sirolimus and everolimus, which are used to prevent the rejection of renal allografts. As kidney diseases continue to escalate worldwide, there is a growing demand for mTOR inhibitors. For instance, in April 2022, the International Society of Nephrology, a US-based worldwide professional group, reported that 843.6 million people worldwide are affected by stages 1-5 of kidney diseases. Over 800 million people around the world, accounting for 10% of the global population, are suffering from chronic renal disease, a degenerative condition. As a result, the upward trend in kidney disease rates is anticipated to drive the growth of the mTOR inhibitors market.

Who Are The Key Players In The [mTOR Inhibitors Industry](#)?

Major players in the mTOR Inhibitors include:

- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals plc
- LC Laboratories
- Exelixis Inc.
- Dr. Reddy's Laboratories Ltd.
- Zydus Lifesciences Limited
- Accord Healthcare Inc.
- Par Pharmaceutical

What Are The Upcoming Trends Of mTOR Inhibitors Market In The Globe?

The mTOR inhibitors market is increasingly being characterized by partnerships and collaborations. Leading businesses in this sector join forces with others to strengthen their position. For instance, Mirati Therapeutics, Inc., a US-based firm working on targeted oncology, entered into a collaboration with Aadi Bioscience, Inc. in October 2022 for an undisclosed sum. This partnership anticipates offering superior benefits to patients suffering from KRAS G12C mutant NSCLC and various other cancer types, using joint strengths of both companies' drugs. Aadi Bioscience, Inc, another US corporation specializing in genetically specific cancer treatments, aims to deliver therapies for cancer patients with mTOR pathway driver alterations. Furthermore, Cambrian Biopharma, a US-based biotech company focusing on longevity with multiple assets, inked a licensing deal with Novartis in February 2022 for an undisclosed amount. The deal's objective is to advance a set of unique and specific compounds that Novartis has developed and defined. These compounds aim to target the mechanistic objective of the rapamycin (mTOR) pathway. Novartis, a Swiss company, is a specialist in researching, developing, creating, and marketing healthcare products, particularly for oncology and other rare diseases.

What Segments Are Covered In The mTOR Inhibitors Market Report?

The mtor inhibitors market covered in this report is segmented –

- 1) By Product Type: Rapamune, Afinitor, Torisel, Zortress, Other Product Types
- 2) By Indication: Oncology, Immunosuppressant, Organ Transplantation, Other Indications
- 3) By Route of Administration: Oral, Intravenous
- 4) By Application: Tumor Treatment, Kidney Transplant, Other Applications
- 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

- 1) By Rapamune: Dosage Forms, Indications
- 2) By Afinitor: Dosage Forms, Indications
- 3) By Torisel: Dosage Forms, Indications
- 4) By Zortress: Dosage Forms, Indications
- 5) By Other Product Types: Experimental MTOR Inhibitors, Generic Versions of MTOR Inhibitors, Combination Therapies with MTOR Inhibitors

View the full mtor inhibitors market report:

<https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report>

Which Region Is Expected To Lead The mTOR Inhibitors Market By 2025?

In 2024, North America held the most significant share in the mTOR inhibitors market. The forecast period, however, predicts Asia-Pacific to exhibit the most rapid growth. The mTOR inhibitors market report encompasses regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global mTOR Inhibitors Market 2025, By [The Business Research Company](#)

Checkpoint Inhibitor Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report>

Her2 Inhibitor Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report>

Interleukin Inhibitor Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/869792260>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.